---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014019"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:15:33.360069+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INVO Fertility divests majority holdings in NTI, retains preferred stake and note

## Summary
- Effective June 2, 2025, INVO redeemed all Series C-1 Preferred for 3,227,813 shares of NTI Class A Common, ceasing to hold NTI common.
- INVO retains 6,300 shares of NTI Series A Preferred, representing 19.9% on an as-converted basis, and a $4.8M secured convertible note from NTI.
- Pro forma net loss improves: Q1 2025 from $17.4M to $16.2M; FY 2024 from $9.1M to $5.7M after removing NTI operations.
- The divestiture removes NTI's intangible assets ($14.8M) and goodwill ($3.0M) from INVO's balance sheet.

## SEC filing metadata
- accession: 0001641172-25-014019
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000164117225014019/0001641172-25-014019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000164117225014019/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014019
- JSON: https://secwatch.observer/filing/0001641172-25-014019.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014019.txt

## Key facts
- M&A Transactions
  INVO Fertility, Inc. completed a disposition (closed 2025-06-02).
  - Action: disposition
  - Closing: 2025-06-02
  source text: Effective June 2, 2025, INVO Fertility, Inc., a Nevada corporation (the “ Company ”) consummated the divestiture of a majority of its holdings in NAYA Therapeutics Inc., a Delaware Corporation (“ NTI ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000164117225014019/0001641172-25-014019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.